Intersurgical has acquired the UroLift System from Teleflex Interventional Urology for an undisclosed amount. This corporate acquisition marks a significant strategic move, bringing the innovative UroLift System, a minimally invasive treatment for benign prostatic hyperplasia (BPH), under Intersurgical's ownership. The UroLift System is specifically designed to address lower urinary tract symptoms caused by an enlarged prostate, offering a unique approach to patient care in the urology sector.
The UroLift System is indicated for the treatment of symptoms of an enlarged prostate up to 100cc in men 45 years or older (50 years outside the U.S.). It stands out as the only BPH procedure that does not require cutting, heating, or removal of prostate tissue, positioning it as a less invasive option for patients. Developed within Teleflex's diverse portfolio of medical technologies, which spans anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology, the UroLift System has been driven by a mission to empower healthcare providers with solutions that improve the health and quality of life for millions of men annually.
This acquisition is strategically aimed at expanding Intersurgical's presence and capabilities within the medical technology landscape, particularly in the urology segment. By integrating the UroLift System, Intersurgical gains a clinically proven and differentiated product that addresses a widespread medical condition. The synergy is expected to leverage Intersurgical's operational strengths and market reach to further advance the availability and adoption of the UroLift System, enhancing its impact on patient outcomes globally.
The combination of Intersurgical's resources with the UroLift System's innovative technology is anticipated to accelerate the development and distribution of BPH solutions. The newly combined entity is poised to continue its mission of improving men's health by providing effective, minimally invasive treatment options to a broader patient population worldwide.